Supraventricular Tachycardia (SVT): What You Need to Understand

The Scene

The following scene is drawn from the composite of patients I have cared for in clinic. All identifying details are changed.

Rachel is 32 years old and lives in Chicago. She has had episodes since she was in college: a sudden racing heart that arrives without warning, lasts between 10 minutes and an hour, and then stops as abruptly as it started. Her primary care physician has told her, on more than one occasion, that it is anxiety. She knows it is not anxiety because she can feel the exact moment it stops, the way a car engine shuts off rather than winding down. Her resting pulse is normal. Her ECGs between episodes are normal. She has had two emergency department visits in six years: both times, by the time the ECG was attached, the episode had already terminated.

At 3 AM on a Tuesday, it happens again. This time she is lying in bed and she is not anxious. She records her pulse on her phone. It reads 195 beats per minute, perfectly regular. She screenshots it. At her next appointment, she brings the screenshot and a description she has rehearsed: “It starts suddenly, out of nowhere. It goes very fast and very regular. Then it stops suddenly. It has happened at least thirty times.”

This time, the word supraventricular tachycardia enters her chart.

SVT is frequently the most misdiagnosed arrhythmia in primary care, attributed to anxiety, panic disorder, or “stress” in a substantial percentage of patients before the correct diagnosis is established 4 / Promising . Understanding what SVT actually is, why it happens, and what can be done about it is the purpose of this article.

What It Is

Supraventricular tachycardia is a broad clinical term for rapid heart rhythms that originate above the ventricles, specifically within or above the atrioventricular (AV) node. In clinical usage, “SVT” most commonly refers to three distinct arrhythmias that share a similar clinical presentation and ECG appearance:

AVNRT (atrioventricular nodal reentrant tachycardia): The most common form, accounting for approximately 60% of SVT cases. The reentrant circuit is confined within or immediately adjacent to the AV node, using two pathways with different conduction speeds and refractory periods.

AVRT (atrioventricular reentrant tachycardia): Accounts for approximately 30% of SVT cases. The circuit involves an accessory pathway: an additional electrical connection between the atria and ventricles that bypasses the AV node. WPW syndrome is the most recognized form of AVRT; however, many accessory pathways are concealed (not visible on the resting ECG) and are only apparent during SVT.

AT (atrial tachycardia): Accounts for approximately 10% of SVT cases. The mechanism is a rapidly firing ectopic focus or a small reentrant circuit confined to the atria. Unlike AVNRT and AVRT, AT can potentially continue even if the AV node is blocked.

The unifying clinical feature: All three produce paroxysmal (sudden onset, sudden offset) tachycardia that is typically narrow-complex on ECG (QRS duration less than 120 ms), regular, and rapid, usually 150-250 bpm. The arrhythmia starts in a moment, runs for a variable duration, and terminates suddenly. This “paroxysmal” quality is diagnostically important and distinguishes SVT from sinus tachycardia, which accelerates and decelerates gradually.

Epidemiology

SVT affects approximately 2.25 per 1,000 persons in the general population 5 / Solid 00878-6). It is substantially more common in women (approximately 2-fold higher age-adjusted incidence) and can occur at any age, including childhood. AVNRT tends to peak in women aged 20-50. AVRT related to accessory pathways is more common in men. SVT has no mortality risk in the absence of structural heart disease or a pre-excitation syndrome, but it significantly impairs quality of life through unpredictable episodes that disrupt work, exercise, and sleep.

The Mechanism

AVNRT: The Two-Pathway Circuit

The AV node has, in most people, two functionally distinct pathways for conducting electrical impulses from the atria to the ventricles:

• The fast pathway: Conducts rapidly but has a longer refractory period (recovers slowly).
• The slow pathway: Conducts slowly but has a shorter refractory period (recovers quickly).

Under normal circumstances, a sinus impulse travels preferentially down the fast pathway, reaching the ventricles quickly. The slow pathway also receives the impulse but arrives late and finds the His bundle already activated; no separate ventricular activation occurs.

The AVNRT circuit is triggered when a premature atrial beat arrives at a moment when the fast pathway is still refractory (from the previous beat) but the slow pathway has already recovered. The impulse travels down the slow pathway and, when it reaches the junction, finds the fast pathway has now recovered. It travels up the fast pathway back to the atria, then down the slow pathway again, creating a continuous loop. The atria are activated almost simultaneously with the ventricles (since retrograde atrial activation occurs nearly simultaneously with antegrade ventricular activation), which produces the characteristic ECG appearance of a narrow tachycardia with either no visible P-waves or P-waves buried within or just after the QRS complex 5 / Solid .

AVRT: The Accessory Pathway

Accessory pathways are extra muscle fibers connecting atria to ventricles outside the normal AV node conduction system. They are congenital variants, present from birth, arising from incomplete fibrous separation of atria and ventricles during cardiac development. In AVRT, the tachycardia circuit uses both the normal AV node (antegrade conduction, atria to ventricles) and the accessory pathway (retrograde conduction, ventricles to atria). Each circuit completion activates the atria and ventricles, producing a rapid regular tachycardia.

The accessory pathway in most AVRT is “concealed”: it can only conduct retrograde (from ventricles to atria) and is not visible on the resting ECG. The delta wave and pre-excitation pattern of WPW syndrome appear only when the accessory pathway also conducts antegrade. The distinction matters clinically: concealed pathways produce only AVRT; manifest pathways (as in WPW) can also produce dangerous rapid conduction of AFib to the ventricles (see SDE-F-RHTM-012).

Atrial Tachycardia

Atrial tachycardia arises from an ectopic automatic focus or a small reentrant circuit confined to the atria. Because the mechanism does not require the AV node as a circuit limb, adenosine may slow the ventricular rate by increasing AV block without terminating the tachycardia itself. This response helps distinguish AT from AVNRT/AVRT, where adenosine terminates the arrhythmia by blocking the AV node, which is an essential part of the circuit.

How We Diagnose

ECG During SVT

The 12-lead ECG during SVT is the key diagnostic tool. The typical findings:

• Rate: 150-250 bpm
• Rhythm: Regular (irregular SVT suggests AFib or AT with variable block)
• QRS duration: Narrow (less than 120 ms) in most cases. Wide-complex SVT occurs when there is aberrant conduction (rate-related bundle branch block) or a pre-excitation pathway.
• P-waves: The location of P-waves relative to QRS provides critical clues:
  • P-waves buried within or just before the QRS (short RP tachycardia): typical AVNRT
  • P-waves immediately after the QRS (short RP, “pseudo-S” in inferior leads): AVNRT or fast-pathway AVRT
  • P-waves midway between QRS complexes (long RP tachycardia): atypical AVNRT or AT

The problem in clinical practice: most SVT episodes terminate before a 12-lead ECG can be obtained, particularly in the emergency department. A resting ECG obtained after termination is normal in most patients with AVNRT or AVRT. It will show delta waves only if the patient also has manifest WPW.

Vagal Maneuvers as a Diagnostic Tool

Before pharmacologic intervention, vagal maneuvers that increase parasympathetic tone and slow AV nodal conduction are both diagnostic and therapeutic for AVNRT and AVRT:

• Standard Valsalva maneuver: Bearing down while holding the breath increases intrathoracic pressure, triggering a reflex increase in vagal tone. Historically performed seated, termination rates are approximately 5-20%.
• Modified Valsalva maneuver (REVERT position): The patient blows into a 10-mL syringe with enough pressure to move the plunger, then is immediately placed supine with legs raised 45 degrees for 15 seconds. The REVERT trial (Appelboam A, et al. Lancet. 2015; DOI: 10.1016/S0140-6736(15)61485-4) enrolled 428 patients and found termination rates of 43% with modified Valsalva versus 17% with standard Valsalva (p<0.001) 5 / Solid . The modified Valsalva is now the guideline-preferred first-line maneuver. Patients can be taught to perform this at home during an SVT episode.
• Carotid sinus massage: Applied by trained practitioners only (due to the rare risk of plaque embolism from carotid artery disease in older patients). Not recommended for home use.

Adenosine

Intravenous adenosine (6-12 mg IV bolus via peripheral or central line with immediate saline flush) is the drug of choice for acute termination of AVNRT and AVRT. It produces a transient complete AV block lasting 10-30 seconds by acting on adenosine A1 receptors in the AV node, interrupting the tachycardia circuit 5 / Solid . The brief pause, followed by resumption of normal sinus rhythm, is both diagnostic and therapeutic.

Adenosine may unmask flutter or AT by slowing the ventricular rate while continuing the atrial arrhythmia. If SVT terminates with adenosine, the diagnosis is AVNRT or AVRT, not AT or flutter (both of which slow but do not terminate with adenosine).

Side effects of adenosine are brief but unpleasant: flushing, chest tightness, and a fleeting sense of impending doom lasting 15-30 seconds. These effects are near-universal and should be warned about before administration.

Electrophysiology Study

When ambulatory monitoring has failed to capture a diagnostic ECG during symptoms, or when the mechanism needs to be precisely characterized before ablation, an electrophysiology (EP) study is performed. In the EP lab, catheters are placed in the heart and programmed stimulation is used to induce the tachycardia under controlled conditions. The circuit is mapped and characterized. In most patients, EP study immediately precedes ablation at the same procedure sitting. The diagnostic value of EP study alone (without proceeding to ablation) is primarily in situations where the arrhythmia cannot be reliably induced or when the patient is not yet committed to ablation.

The Evidence

Catheter Ablation: High Cure Rates with Low Risk

Catheter ablation is the definitive treatment for symptomatic SVT. The target varies by mechanism:

AVNRT ablation: The slow pathway within or adjacent to the AV node is ablated using radiofrequency or cryoenergy. The slow pathway carries the slow-conducting limb of the reentrant circuit; eliminating it interrupts the circuit without disrupting normal AV conduction. Single-procedure success rates exceed 95% for AVNRT 5 / Solid . The primary risk is inadvertent complete AV block requiring a pacemaker, occurring in approximately 0.5-1% of cases at experienced centers. Cryoablation may have a lower AV block risk than radiofrequency for AVNRT because cryolesions are reversible at intermediate temperatures, allowing the operator to test the effect before committing to a permanent lesion.

AVRT ablation (accessory pathway): The accessory pathway is located using activation mapping during tachycardia or pace mapping, then ablated at the precise site of earliest activation. Single-procedure success rates are approximately 90-95% depending on pathway location. Pathways near the normal conduction system (para-Hisian, midseptal) carry higher risk of inadvertent AV block than free-wall pathways. Overall complication rates are low at experienced centers.

AT ablation: Success rates are somewhat lower (approximately 80-90%) because focal ATs can arise from multiple locations within the atria and some are difficult to induce reproducibly.

The ACC/AHA/HRS guidelines recommend catheter ablation as Class I for patients with SVT who are symptomatic and prefer ablation over medication, and as Class IIa for patients in whom medication has failed or is not tolerated 5 / Solid .

Medical Therapy: Acute and Long-Term

For patients who either choose not to have ablation or who are awaiting ablation, medical options include:

Acute termination: Modified Valsalva maneuver (first line, as above), then adenosine (second line), then IV verapamil or diltiazem (third line for hemodynamically stable patients without pre-excitation), then electrical cardioversion for hemodynamically unstable patients.

Long-term suppression: Daily beta-blockers or non-dihydropyridine calcium channel blockers (verapamil, diltiazem) reduce SVT frequency and duration but do not reliably prevent all episodes 4 / Promising . Flecainide and propafenone may be more effective for some patients but require careful patient selection (no structural heart disease, no WPW).

The data on “pill-in-pocket” therapy: for patients with infrequent episodes of known SVT who are not on daily therapy, a single oral dose of diltiazem plus propranolol taken at the onset of an episode can terminate SVT within 30 minutes in approximately 90% of cases when the diagnosis has been established 4 / Promising . This strategy requires prior EP evaluation to confirm the diagnosis and exclude pre-excitation.

The Anxiety Misdiagnosis Problem

The diagnostic delay for SVT is a real and documented clinical problem. Lessmeier and colleagues demonstrated that the average time from symptom onset to SVT diagnosis was 3.3 years, with 54% of patients receiving a diagnosis of “panic disorder,” “anxiety,” or “somatization” during the delay period 4 / Promising . The discriminating feature of SVT that separates it from anxiety is the abrupt onset and offset, the precise regularity at high rates, and the absence of any psychological trigger in many episodes. Patients who recognize this pattern should ask for ambulatory monitoring and a referral to a cardiologist.

Sex Differences in SVT

Women are more likely to be diagnosed with AVNRT and are more likely to experience SVT during pregnancy, when the combination of increased blood volume, heart rate, and circulating catecholamines lowers the threshold for arrhythmia induction 5 / Solid 00290-8). Women with SVT during pregnancy are at no increased obstetric risk from the arrhythmia itself in the absence of structural heart disease, but the emotional burden of palpitations in pregnancy is substantial. Catheter ablation is typically deferred until after delivery unless the arrhythmia is severe or refractory to medical therapy, in which case ablation with lead shielding can be performed safely.

Women are more likely to be told their SVT is anxiety than men presenting with identical symptoms 4 / Promising . The gender dimension of diagnostic delay for SVT mirrors the broader pattern of cardiac symptoms in women being attributed to psychological causes at higher rates than in men.

The Patient Experience

What SVT Feels Like

The hallmark of SVT is sudden onset. The patient is sitting quietly, running, sleeping, or driving, and the heart abruptly changes to a rate that can be perceived as a pounding, fluttering, or drumming sensation in the chest or throat. Most patients know the exact moment it starts and the exact moment it ends. Commonly reported additional symptoms:

• Neck pulsation: in AVNRT, because the atria and ventricles contract simultaneously, the atria contract against closed tricuspid and mitral valves, producing a pulsation in the neck veins
• Lightheadedness or presyncope at very high rates (above 200 bpm)
• Polyuria: a distinctive symptom of SVT in which the kidneys release excess urine during the episode, driven by atrial natriuretic peptide released from the stretched atria contracting against closed valves
• Anxiety or fear during the episode, not causing it

Syncope during SVT is uncommon but can occur when the rate is extremely fast (above 240 bpm) or when the patient is standing. Frank syncope during SVT warrants urgent evaluation to exclude a pre-excitation syndrome.

What Your Doctor Will Not Have Time to Explain

1. You can terminate your own SVT with the modified Valsalva. The REVERT technique (blow into a 10-mL syringe, then immediately lie down with legs raised for 15 seconds) terminates SVT in 43% of attempts. Ask your cardiologist to demonstrate the technique and confirm you are performing it correctly.

2. The anxiety diagnosis delay is common. If you have been told for years that your palpitations are anxiety and the episodes are sudden-onset, sudden-offset, and perfectly regular, ask for a 14-day Zio patch or KardiaMobile prescription to capture the next episode. The ECG during the episode is the diagnostic document.

3. SVT ablation has a very high cure rate. For AVNRT and AVRT, single-procedure success rates exceed 95% and 90% respectively. For most patients who choose ablation, the SVT is gone. The procedure is not experimental or high-risk in experienced hands.

4. Polyuria after SVT is normal. The release of atrial natriuretic peptide during SVT (when stretched atria contract against closed valves) produces a predictable increase in urine output after the episode terminates. This is not a kidney problem.

5. SVT in pregnancy is manageable. If you are pregnant and developing SVT, the modified Valsalva maneuver and adenosine in the emergency setting are both safe in pregnancy. Beta-blockers (metoprolol, atenolol) are the preferred daily medication during pregnancy when daily therapy is needed, with attention to fetal heart rate monitoring.

Decisions and Trade-Offs

Ablation vs. Long-Term Medical Therapy

For most patients with symptomatic, recurrent SVT, the decision between ablation and medication is not whether to treat but how. The arguments favor ablation for most patients:

• Cure rates of 90-95% for AVNRT/AVRT versus symptom reduction (not cure) with medications
• Freedom from daily medications and their side effects
• One-time cost of the procedure versus years of medication cost and monitoring
• Better quality of life outcomes in trials comparing ablation to medical therapy

The arguments that support trying medical therapy first:

• Patient preference to avoid an invasive procedure
• Infrequent and well-tolerated episodes that respond reliably to the modified Valsalva maneuver
• Young patients in whom very long-term follow-up after ablation is still limited (though data out to 10-15 years are reassuring)
• SVT occurring in a context that may be temporary (pregnancy, acute illness, stimulant use)

Cost and Access

Three Questions to Ask Your Cardiologist

1. “What type of SVT do I have, and does knowing the mechanism (AVNRT, AVRT, AT) change the risk or success rate of ablation for my case?”
2. “If I choose ablation, what is the specific risk of complete AV block at your center, and what are the most common complications you see?”
3. “If I choose medication first, what is the plan if my SVT continues to occur, and when would you recommend switching to ablation?”

The SDE Synthesis

SVT occupies a unique position in the Stop Dying Early framework: it is the arrhythmia that has no mortality in the absence of structural heart disease, yet it produces years of diagnostic delay, medical misattribution, and quality-of-life impairment in patients who are often young, otherwise healthy, and told repeatedly that nothing is wrong.

The SDE commitment is not only to preventing death. It is to preventing the years of uncertainty that erode quality of life before a correct diagnosis is established. For patients with SVT, that commitment means making the diagnostic path clear: document the episode, establish the mechanism, make an informed decision about ablation versus medical therapy. The SDE Audit is the starting point for establishing baseline cardiac health in patients with palpitations, ruling out structural heart disease, and ensuring the right monitoring strategy is in place to capture the arrhythmia.

Cross-links within the SDE system: The Foundations article on Wolff-Parkinson-White (SDE-F-RHTM-012) provides the full clinical picture for patients with pre-excitation and AVRT. The Foundations article on Cardiac Ablation (SDE-F-PROC-007) covers the EP lab procedure in detail. The Foundations article on the Zio Patch (SDE-F-DEVI-005) covers extended ambulatory monitoring for arrhythmia diagnosis. For patients with SVT in the context of a structural heart condition, the Foundations articles on HCM (SDE-F-FAIL-007) and valvular disease are relevant.